Email this article USE OF TARGET DRUGS IN A HETEROGENEOUS POPULATION OF PATIENTS WITH METASTATIC KIDNEY CANCER
- Authors: Alekseev B.Y.1,2, Kalpinskiy A.S.1,2
-
Affiliations:
- Department of Oncourology, P.A. Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of the Russian Federation
- Department of Urology with a Course of Oncourology, Faculty for Postgraduate Training of Medical Workers, Russian Peoples Friendship University
- Issue: Vol 7, No 1 (2011)
- Pages: 20-24
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.03.2011
- URL: https://oncourology.abvpress.ru/oncur/article/view/46
- DOI: https://doi.org/10.17650/1726-9776-2011-7-1-20-24
- ID: 46
Cite item
Full Text
Abstract
The majority of clinical trials included a thoroughly selected population of patients predominantly with clear-cell renal cell carcinoma (RCC), without brain metastases and with a good somatic status. Due to the fact that in routine practice, the patient population is more heterogeneous (patients with non-clear cell RCC, brain metastases, and an ECOG somatic status of > 1, the questions arise of whether it is effective and expedient to use target drugs in this group of patients. The results of clinical trials of sunitinib with extended inclusion criteria and those of the Phase III randomized study of temsirolimus confirmed the clinical efficacy of both agents in the treatment of patients with a poor disease prognosis, non-clear cell RCC and elderly subjects > 65 years (Memorial Sloan-Kettering Cancer Center). Objective response rates and overall survival without progression were lower in this category of patients versus those with clear-cell RCC, which is likely to be due to the small number of such patients and to the lack of data of the current randomized controlled clinical trials.
About the authors
B. Ya. Alekseev
Department of Oncourology, P.A. Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of the Russian Federation; Department of Urology with a Course of Oncourology, Faculty for Postgraduate Training of Medical Workers, Russian Peoples Friendship University
Author for correspondence.
Email: byalekseev@mail.ru
Department of Oncourology Russian Federation
A. S. Kalpinskiy
Department of Oncourology, P.A. Herzen Moscow Oncology Research Institute, Ministry of Health and Social Development of the Russian Federation; Department of Urology with a Course of Oncourology, Faculty for Postgraduate Training of Medical Workers, Russian Peoples Friendship University
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
